MECHELEN, Belgium I October 9, 2014 I Galapagos NV (GLPG.NX) presents a poster today disclosing the discovery process for novel, complementary corrector series that restore the CFTR function in a new way at the North American Cystic Fibrosis Conference in Atlanta, USA. These novel corrector series, both in combination with potentiator GLPG1837, and with GLPG1837 and a prototype corrector C18, restore >40% of healthy function in cells from patients with the most common mutation, delF508. Galapagos is among the first to pass this hurdle pre-clinically. Galapagos plans to enter Phase 1 with potentiator GLPG1837 and select a pre-clinical candidate corrector before end 2014.
Poster & Session Details
“Novel corrector, potentiator combinations for treating cystic fibrosis”
Dr Katja Conrath presenting
Abstract #52
Poster Session I, Thursday 9 October and Poster Session II, Friday 10 October, 2014 Galapagos presents the discovery process used to identify completely novel corrector series which modulate CFTR maturation and trafficking processes in a specific and different way. Pre-clinical data is shown in which these novel corrector series in combination with existing CFTR modulators achieve restoration of at least 40% of healthy CFTR in cells from CF patients with the most common mutation, delF508. Galapagos aims to develop combinations of corrector and potentiator medicines to address the needs of this largest CF patient group. The poster is available on the Galapagos website, www.glpg.com.
Earlier this year, Galapagos presented preclinical data on five different Galapagos corrector series that in combination with potentiator GLPG1837 restore up to 60% of healthy function in delF508 patient cells; see the R&D Update 2014 slides on www.glpg.com for more information.
The North American Cystic Fibrosis Conference is sponsored by the Cystic Fibrosis Foundation.
For more information on cystic fibrosis, please go to www.cff.org.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a large pipeline comprising three Phase 2 studies, two Phase 1 studies, five pre-clinical, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications. In the field of inflammation, AbbVie and Galapagos signed an agreement for the development and commercialization of GLPG0634. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn’s disease. Galapagos has another selective JAK1 inhibitor, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). GLPG0974 is the first inhibitor of FFA2 to be evaluated clinically for the treatment of IBD; this program has completed a Proof-of-Concept Phase 2 study. GLPG1205 is a first-in-class molecule that targets inflammatory disorders and has completed Phase 1. GLPG1690 is a first-in-class compound that targets pulmonary diseases and is currently in a Phase 1 study. AbbVie and Galapagos signed an agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is at the pre-clinical candidate stage. The Galapagos Group, including fee-for-service subsidiary Fidelta, has around 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. Further information at: www.glpg.com.
SOURCE: Galapagos
Post Views: 92
MECHELEN, Belgium I October 9, 2014 I Galapagos NV (GLPG.NX) presents a poster today disclosing the discovery process for novel, complementary corrector series that restore the CFTR function in a new way at the North American Cystic Fibrosis Conference in Atlanta, USA. These novel corrector series, both in combination with potentiator GLPG1837, and with GLPG1837 and a prototype corrector C18, restore >40% of healthy function in cells from patients with the most common mutation, delF508. Galapagos is among the first to pass this hurdle pre-clinically. Galapagos plans to enter Phase 1 with potentiator GLPG1837 and select a pre-clinical candidate corrector before end 2014.
Poster & Session Details
“Novel corrector, potentiator combinations for treating cystic fibrosis”
Dr Katja Conrath presenting
Abstract #52
Poster Session I, Thursday 9 October and Poster Session II, Friday 10 October, 2014 Galapagos presents the discovery process used to identify completely novel corrector series which modulate CFTR maturation and trafficking processes in a specific and different way. Pre-clinical data is shown in which these novel corrector series in combination with existing CFTR modulators achieve restoration of at least 40% of healthy CFTR in cells from CF patients with the most common mutation, delF508. Galapagos aims to develop combinations of corrector and potentiator medicines to address the needs of this largest CF patient group. The poster is available on the Galapagos website, www.glpg.com.
Earlier this year, Galapagos presented preclinical data on five different Galapagos corrector series that in combination with potentiator GLPG1837 restore up to 60% of healthy function in delF508 patient cells; see the R&D Update 2014 slides on www.glpg.com for more information.
The North American Cystic Fibrosis Conference is sponsored by the Cystic Fibrosis Foundation.
For more information on cystic fibrosis, please go to www.cff.org.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a large pipeline comprising three Phase 2 studies, two Phase 1 studies, five pre-clinical, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications. In the field of inflammation, AbbVie and Galapagos signed an agreement for the development and commercialization of GLPG0634. GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn’s disease. Galapagos has another selective JAK1 inhibitor, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012). GLPG0974 is the first inhibitor of FFA2 to be evaluated clinically for the treatment of IBD; this program has completed a Proof-of-Concept Phase 2 study. GLPG1205 is a first-in-class molecule that targets inflammatory disorders and has completed Phase 1. GLPG1690 is a first-in-class compound that targets pulmonary diseases and is currently in a Phase 1 study. AbbVie and Galapagos signed an agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is at the pre-clinical candidate stage. The Galapagos Group, including fee-for-service subsidiary Fidelta, has around 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. Further information at: www.glpg.com.
SOURCE: Galapagos
Post Views: 92
